Pacific Biosciences of California Inc. (PacBio) reported its financial results for the fourth quarter (Q4) and full year (FY) 2025. For Q4 2025, PacBio posted total revenue of USD 44.65 million, which included product revenue of USD 38.97 million and service and other revenue of USD 5.68 million. For the full year 2025, total revenue reached USD 160.01 million, with product revenue at USD 135.76 million and service and other revenue at USD 24.25 million. Cost of product revenue for Q4 2025 was USD 24.20 million, while for the full year 2025, it amounted to USD 89.76 million. During the quarter ended December 31, 2024, PacBio recorded a gain related to a convertible notes exchange transaction. PacBio continues to provide solutions for a broad range of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. The company’s products are for research use only and not for diagnostic procedures. PacBio presented both GAAP and non-GAAP financial measures, with management emphasizing that non-GAAP metrics exclude certain recurring and infrequent charges to assist investors in analyzing the company’s operating performance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.